Avenue Therapeutics, Inc. (ATXI) EPS Estimated At $-0.93

July 14, 2018 - By Margaret Guttierez

Analysts expect Avenue Therapeutics, Inc. (NASDAQ:ATXI) to report $-0.93 EPS on August, 10.They anticipate $0.39 EPS change or 72.22 % from last quarter’s $-0.54 EPS. After having $-1.03 EPS previously, Avenue Therapeutics, Inc.’s analysts see -9.71 % EPS growth. The stock increased 6.50% or $0.24 during the last trading session, reaching $3.93. About 69,993 shares traded or 66.60% up from the average. Avenue Therapeutics, Inc. (NASDAQ:ATXI) has 0.00% since July 14, 2017 and is . It has underperformed by 12.57% the S&P500.

Avenue Therapeutics, Inc., a specialty pharmaceutical company, acquires, licenses, develops, and commercializes an intravenous formulation of tramadol HCI principally for use in the acute/intensive care hospital setting. The company has market cap of $41.47 million. The Company’s product candidate is IV Tramadol for the treatment of post-operative pain. It currently has negative earnings. The firm was founded in 2015 and is based in New York, New York.

More notable recent Avenue Therapeutics, Inc. (NASDAQ:ATXI) news were published by: Seekingalpha.com which released: “Avenue Therapeutics Is On To Something” on June 26, 2018, also Schaeffersresearch.com with their article: “Analyst: This Drug Stock Could Rally 173%” published on June 25, 2018, Streetinsider.com published: “Oppenheimer Starts Avenue Therapeutics (ATXI) at Outperform” on July 12, 2018. More interesting news about Avenue Therapeutics, Inc. (NASDAQ:ATXI) were released by: Schaeffersresearch.com and their article: “3 Healthcare Stocks Making Massive Moves” published on July 13, 2018 as well as Streetinsider.com‘s news article titled: “UPDATE: HC Wainwright Starts Avenue Therapeutics (ATXI) at Buy, Sees Multiple NT Catalysts” with publication date: June 25, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.